Cantor Fitzgerald Issues Positive Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Cantor Fitzgerald lifted their FY2025 earnings estimates for Zevra Therapeutics in a research report issued on Thursday, July 10th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of $1.58 per share for the year, up from their previous forecast of ($0.17). Cantor Fitzgerald has a "Overweight" rating and a $29.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Cantor Fitzgerald also issued estimates for Zevra Therapeutics' FY2026 earnings at $0.77 EPS.

ZVRA has been the subject of several other research reports. HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target for the company. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $23.71.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA traded down $0.09 on Monday, reaching $12.71. 228,750 shares of the company's stock were exchanged, compared to its average volume of 720,384. The business's 50-day moving average is $9.06 and its two-hundred day moving average is $8.20. The firm has a market capitalization of $694.71 million, a price-to-earnings ratio of -6.70 and a beta of 1.97. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. Zevra Therapeutics has a fifty-two week low of $5.45 and a fifty-two week high of $12.98.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same period in the prior year, the firm earned ($0.40) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Woodline Partners LP boosted its holdings in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock worth $34,571,000 after buying an additional 476,032 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Zevra Therapeutics by 462.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock worth $30,441,000 after purchasing an additional 3,001,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Zevra Therapeutics by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock worth $23,554,000 after purchasing an additional 68,151 shares in the last quarter. Altium Capital Management LLC lifted its position in shares of Zevra Therapeutics by 8.8% in the fourth quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after purchasing an additional 150,000 shares in the last quarter. Finally, AIGH Capital Management LLC lifted its position in shares of Zevra Therapeutics by 82.4% in the first quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company's stock worth $10,771,000 after purchasing an additional 649,495 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.